flupentixol/melitracen / Generic mfg. - LARVOL DELTA

Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain-bladder axis. (PubMed, Sci Rep) - P4 | "Patients in the control group (n = 62) received omeprazole for 4 weeks. Further studies are needed to confirm about brain-gut-bladder axis in EPS pathogenesis. Clinical Trials.gov (number: ChiCTR2400079677)."

Clinical • Journal • CNS Disorders • Depression • Dyspepsia • Musculoskeletal Pain • Pain • Psychiatry

Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial. (PubMed, Technol Health Care) - "They were administered with ebastine (Group A) or ebastine combined with flupentixol and melitracen (Group B) for 4 weeks. After treatment, the serum levels of D-LAC and I-FABP were significantly lower in Group B than in Group A.ConclusionRefractory IBS patients showed certain psychological abnormalities. Ebastine combined with antidepressants exhibited more obvious benefits on QOL, sleep quality, and SSS, with significant improvements in psychological status and intestinal permeability in refractory IBS patients."

Journal • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Effectiveness of simultaneous electroacupuncture stimulation on the tibial and ilioinguinal-iliohypogastric nerves in the treatment of refractory overactive bladder syndrome in women. (PubMed, Curr Urol) - "All patients in both groups had received anticholinergic muscarinic receptor antagonists (tolterodine/solifenacin), β3 receptor agonists, flupentixol/melitracen, and other basic treatment regimens with poor results. This therapy is safe, convenient, and free of significant adverse reactions, providing a new approach for the clinical treatment of refractory OAB in these patients. It significantly improves bladder symptoms and alleviates anxiety and depression, thereby markedly enhancing the patients' quality of life."

Journal • CNS Disorders • Depression • Mood Disorders • Overactive Bladder • Psychiatry • Urology

Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease (clinicaltrials.gov) - P=N/A | N=120 | Not yet recruiting | Sponsor: RenJi Hospital

New trial • Gastroenterology • Gastroesophageal Reflux Disease

Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: RenJi Hospital

New trial • Dyspepsia

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

New P4 trial • Ophthalmology • Thyroid Eye Disease

Treatment indications for antidepressants prescribed in primary health care facilities in Beijing, China. (PubMed, Int Psychogeriatr) - "For these indications, the most frequently prescribed antidepressant was flupentixol/melitracen and sertraline.For 36.32 % of all antidepressant prescriptions,physicians prescribed a drug for an off-label indication,especially insomnia and pain.Physicians also prescribed antidepressants for several indications that were off-label for all antidepressants, including digestive system disorders and migraine. This study found compound antidepressants are widely prescribed and used off-label indications.There is a need for more evidence to evaluate the clinical outcomes associated with off-label antidepressant indications for older adults to optimise prescribing decisions at PHFs."

Journal • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Insomnia • Migraine • Mood Disorders • Pain • Psychiatry • Sleep Disorder

A Case of Pseudo Prolactin Elevation Caused by Medication. (PubMed, Clin Lab) - "Only effective communication between laboratory and clinical departments can make laboratory results more accurate and provide strong guarantees for clinical diagnosis and treatment."

Journal • Breast Cancer • Endocrine Cancer • Oncology • Pituitary Gland Carcinoma • Psychiatry • Solid Tumor

Antidepressant-induced Hyponatremia in Postmenopausal Females: A Case Series. (PubMed, J Midlife Health) - "The exact mechanism of hyponatremia with the use of antidepressants is not known; however, syndrome of inappropriate antidiuretic hormone secretion (SIADH) is presumed to be the reason. Here, we report two cases of antidepressant drug-induced hyponatremia in two postmenopausal females with no other risk factor for hyponatremia: one associated with mirtazapine and the other with flupentixol/melitracen."

Journal • Cardiovascular • Heart Failure

Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia (clinicaltrials.gov) - P=N/A | N=88 | Recruiting | Sponsor: Air Force Military Medical University, China

New trial • CNS Disorders • Dyspepsia

A multicenter retrospective study of antidepressant use in outpatient clinics in China pre- and post-COVID. (PubMed, Int J Clin Pharm) - "Over the past 5 years, both the number of patients and antidepressant prescriptions have shown upward trends, and the COVID-19 pandemic has impacted prescribing. Understanding the changes in antidepressant prescriptions can identify adherence to national guidelines."

Journal • Retrospective data • CNS Disorders • Depression • Infectious Disease • Novel Coronavirus Disease • Psychiatry

The efficacy and safety of NeuroWell antidepressant dietary supplement, Deanxit, and their combination in the treatment of mild-to-moderate depression: A randomized clinical trial. (PubMed, Genes Dis) - No abstract available

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Sex differences among patients with intentional poisoning presenting to the emergency Department at a Tertiary Care Centre in Beirut, Lebanon. (PubMed, Basic Clin Pharmacol Toxicol) - "Women exhibited a higher likelihood of exposures to sedatives/hypnotics/antipsychotics, antihistamines and melitracen/flupentixol, while stimulant drugs, ethanol, and opioids were prevalent in men. Developing proper and effective sex-specific measures may mitigate potential physical and psychological consequences."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders

Effectiveness and Safety of Flupentixol and Melitracen Tablets for the Treatment of Patients with Persistent Idiopathic Facial Pain: A Retrospective Observational Study. (PubMed, Pain Physician) - "FM tablets showed its potential in the management of PIFP with considerable efficacy and safety. Early administration of FM tablets after a PIFP diagnosis may result in a high possibility of pain relief."

Journal • Observational data • Retrospective data • CNS Disorders • Depression • Pain • Psychiatry

Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis. (PubMed, J Headache Pain) - "Migraine treatment gradually converges toward evidence-based and guideline-recommended treatment. Attention should be given to opioid prescribing, weak evidence-based antidepressant use, and medication overuse in migraine treatment."

Journal • Retrospective data • CNS Disorders • Migraine • Pain

Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "Surface Under the Cumulative Ranking results indicated that the top three treatments with the best response rate were possibly Guipiwan, Ease Pill, and Chaihu Jia Longgu Muli Decoction; the top three treatments on the reduction of HAMD scores were Chai Hu Shu Gan San, Xingnao Jieyu Decoction, and Xiaoyao Powder; and the top three treatments with the lowest adverse effects rates were Xiaoyao Powder, Alprazolam, and Xingnao Jieyu Decoction. Interestingly, commonly used synthetic drugs such as Fluoxetine, Escitalopram, Amitriptyline, Sertraline, Flupentixol and Melitracen, and Venlafaxine, not only appeared to be less effective than specific Chinese herbal medicines (Gan Mai Da Zao Decoction, Chaihu Jia Longgu Muli Decoction, Chai Hu Shu Gan San, Danzhi-Xiaoyao-San, and Xingnao Jieyu Decoction), but they were also related to substantially higher risk of adverse events...However, it underscores the necessity for larger, methodologically robust trials to further validate and..."

Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

Beyond the counter: Navigating the landscape of Deanxit® dispensing - Insights from Jordanian community pharmacies. (PubMed, Heliyon) - "This study provides valuable insights into the current landscape of Deanxit® dispensing patterns, pharmacists' poor knowledge levels, and malpractices in Jordan. By identifying areas for improvement and offering recommendations for intervention, this study contributes to enhancing pharmacy practice and patient care outcomes in the region."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression. (PubMed, Mol Neurobiol) - "In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hydrochloride orally. HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P < 0.05); HAMD and NIHSS were compared among groups, time, and interaction (P < 0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value."

Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry • BDNF • NGF

Efficacy and safety of eszopiclone combined with drug therapy in the treatment of insomnia after stroke: A network meta-analysis and systematic review. (PubMed, PLoS One) - "Multi-drug therapy based on eszopiclone can effectively improve the sleep quality of patients with insomnia after stroke, and ESZ+SDOL has significant efficacy and safety. However, due to the limitations of this study, efficacy ranking cannot fully explain the superiority or inferiority of clinical efficacy. In the future, more multicentre, large sample, double-blind randomized controlled trials are needed to supplement and demonstrate the results of this study."

Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Insomnia • Pain • Sleep Disorder

Effects of Jiawei Yiqihuoxue decotion for the treatment of post stroke depression and anxiety. (PubMed, Medicine (Baltimore)) - "All patients received flupentixol and melitracen and were divided into treatment (n = 36) and control (n = 36) groups...This study found that the JWYQHXD may help improve the quality of life of patients with PSDA. Future prospective studies are warranted to confirm these findings."

Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry

Anesthesia management of patients with laryngeal cancer who did not stop using Flupentixol/Melitracen tablets before surgery. (PubMed, Asian J Surg) - No abstract available

Journal • Surgery • Anesthesia • Bipolar Disorder • CNS Disorders • Head and Neck Cancer • Laryngeal Cancer • Oncology • Psychiatry • Solid Tumor

Observation of the clinical therapeutic effect of mosapride citrate dispersible tablets in combination with flupentixol and melitracen tablets in the treatment of functional dyspepsia in the elderly (IDDF 2023) - "The difference in recurrence rate between the two groups was statistically significant after 6 months of treatment (P < 0.05); no side reactions related to medications were observed in both groups. Conclusions The treatment of mosapride citrate dispersible tablets combined with flupentixol and melitracen tablets for FD patients have ideal efficacy effects, a lower recurrence rate in long-term observation, and the patient has no obvious symptoms of adverse events, the profound clinical treatment value of popularization."

Clinical • Combination therapy • Dyspepsia

Melitracen and flupentixol (deanxit) use disorder in Lebanon. (PubMed, Heliyon) - "Deanxit use disorder is underrecognized among Lebanese patients. Most of our patients were prescribed Deanxit by their physicians but reported inadequate knowledge of its side effects and risk of abuse."

Journal • Mood Disorders • Psychiatry

Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study. (PubMed, Ther Adv Respir Dis) - "This is the first report that fully represented a guideline-led treatment protocol for refractory chronic cough (RCC) based on a large series of patients, which evaluated the short- and long-term effects of the currently available treatments for RCC. We found that the therapeutic trial of different neuromodulators is a pragmatic strategy, which helped around two-thirds of patients. Gabapentin, deanxit (flupentixol/melitracen), and baclofen had similar therapeutic outcomes. This study may offer real-world experience for the future management of RCC."

Journal • Real-world • Real-world evidence • Retrospective data • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial. (PubMed, Front Psychiatry) - P=N/A | "Participants (N = 240) were randomly allocated to receive flupentixol-melitracen (FM) plus omeprazole therapy for 2 (SC group) or 4 (LC group) weeks, respectively. Compared to 4-week FM therapy, the 2-week FM therapy reduces the risk of ADS with non-inferior treatment efficacy in patients with rFD. Clinical trials.gov, identifier NCT05099913."

Clinical • Journal • CNS Disorders • Depression • Dyspepsia • Gastrointestinal Disorder • General Anxiety Disorder • Mood Disorders • Psychiatry • Psychosomatic Disorders